Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma

Hau, Peter, Fabel, Klaus, Baumgart, Ulrike, Rümmele, Petra, Grauer, Oliver, Bock, Annekatrin, Dietmaier, Christopher, Dietmaier, Wolfgang, Dietrich, Jörg, Dudel, Christine, Hübner, Franz, Jauch, Tanya, Drechsel, Elisabeth, Kleiter, Ingo, Wismeth, Cäcile, Zellner, Anton, Brawanski, Alexander, Steinbrecher, Andreas, Marienhagen, Jörg, Bogdahn, Ulrich · 2004 · Cancer

Abstract

BACKGROUND: Doxorubicin exhibits high efficacy in malignant glioma cell cultures. Nonetheless, as a standard formulation, doxorubicin has not been used clinically, due to poor penetration of the blood‐brain barrier. Furthermore, doxorubicin is known to induce tumor resistance genes. To address both of these issues, the authors investigated the use of pegylated liposomal doxorubicin (Caelyx™; Essex Pharma, Munich, Germany) alone (Trial 1) and in combination with tamoxifen (Trial 2) in two sequentially performed nonrandomized prospective Phase II trials involving patients with recurrent high‐grade glioma. METHODS: Twenty patients were included in each trial. Progression‐free survival at 6 months (PFS‐6) and toxicity were the primary endpoints. Expression of the tumor resistance proteins multidrug resistance protein 1 (MDR‐1) and multiple resistance protein (MRP) was evaluated by immunohistochemical methods and by sestamibi–single‐photon emission computed tomography (SPECT). RESULTS: The overall response rate (including cases of disease stabilization) was 40% in both Trial 1 and Trial 2. PFS‐6 was 15%, and the median time to disease progression was 17 weeks. It is noteworthy that 40% of patients with Grade III tumors had long‐term responses, which lasted for up to 3 years. There was no significant difference between Trial 1 and Trial 2 in terms of efficacy. Both regimens were well tolerated, with the main side effect being palmoplantar erythrodysesthesia. The authors found no correlation between clinical response and expression of tumor resistance genes or between clinical response and SPECT data. CONCLUSIONS: Pegylated liposomal doxorubicin administered alone or in combination with tamoxifen is safe and moderately effective in patients with recurrent high‐grade glioma. None of the putative predictors for response that were evaluated proved to be significant in this setting. Cancer 2004. © 2004 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.20073

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 196

Metadata

Authors
Hau, P., Fabel, K., Baumgart, U., Rümmele, P., Grauer, O., Bock, A., Dietmaier, C., Dietmaier, W., Dietrich, J., Dudel, C., Hübner, F., Jauch, T., Drechsel, E., Kleiter, I., Wismeth, C., Zellner, A., Brawanski, A., Steinbrecher, A., Marienhagen, J., & Bogdahn, U.
Venue
Cancer
Publisher
Wiley
Published
2004-02-06
Volume
100
Issue
6
Pages
1199-1207
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2081215365
Cited by
196
References
3
FWCI
5.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.